AU2001270932A1 - Particulate composition of eletriptan showing a sigmoidal pattern of controlled release - Google Patents

Particulate composition of eletriptan showing a sigmoidal pattern of controlled release

Info

Publication number
AU2001270932A1
AU2001270932A1 AU2001270932A AU7093201A AU2001270932A1 AU 2001270932 A1 AU2001270932 A1 AU 2001270932A1 AU 2001270932 A AU2001270932 A AU 2001270932A AU 7093201 A AU7093201 A AU 7093201A AU 2001270932 A1 AU2001270932 A1 AU 2001270932A1
Authority
AU
Australia
Prior art keywords
composition
eletriptan
pharmaceutically acceptable
core
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001270932A
Other languages
English (en)
Inventor
Manaud Pierre Frederick De Raspide
Ross James Macrae
Mathias Walther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AU2001270932A1 publication Critical patent/AU2001270932A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
AU2001270932A 2000-08-02 2001-07-18 Particulate composition of eletriptan showing a sigmoidal pattern of controlled release Abandoned AU2001270932A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0018968.8A GB0018968D0 (en) 2000-08-02 2000-08-02 Particulate composition
GB0018968.8 2000-08-02
PCT/IB2001/001279 WO2002009675A1 (en) 2000-08-02 2001-07-18 Particulate composition of eletriptan showing a sigmoidal pattern of controlled release

Publications (1)

Publication Number Publication Date
AU2001270932A1 true AU2001270932A1 (en) 2002-02-13

Family

ID=9896843

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001270932A Abandoned AU2001270932A1 (en) 2000-08-02 2001-07-18 Particulate composition of eletriptan showing a sigmoidal pattern of controlled release

Country Status (38)

Country Link
US (1) US20020034545A1 (pt)
EP (1) EP1365748B1 (pt)
JP (1) JP2004505034A (pt)
KR (1) KR20030024820A (pt)
CN (1) CN1630511A (pt)
AP (1) AP2001002233A0 (pt)
AR (1) AR030099A1 (pt)
AT (1) ATE308978T1 (pt)
AU (1) AU2001270932A1 (pt)
BG (1) BG107361A (pt)
BR (1) BR0112839A (pt)
CA (1) CA2417887C (pt)
CZ (1) CZ2003241A3 (pt)
DE (1) DE60114887T2 (pt)
EA (1) EA200300110A1 (pt)
EC (1) ECSP034451A (pt)
EE (1) EE200300051A (pt)
ES (1) ES2250429T3 (pt)
GB (1) GB0018968D0 (pt)
GT (1) GT200100149A (pt)
HR (1) HRP20030036A2 (pt)
HU (1) HUP0301453A2 (pt)
IL (1) IL153494A0 (pt)
IS (1) IS6649A (pt)
MA (1) MA26934A1 (pt)
MX (1) MXPA03000999A (pt)
NO (1) NO20030498D0 (pt)
NZ (1) NZ522976A (pt)
OA (1) OA12348A (pt)
PA (1) PA8523101A1 (pt)
PE (1) PE20020385A1 (pt)
PL (1) PL359847A1 (pt)
SK (1) SK1082003A3 (pt)
SV (1) SV2002000574A (pt)
TN (1) TNSN01115A1 (pt)
UY (1) UY26861A1 (pt)
WO (1) WO2002009675A1 (pt)
ZA (1) ZA200300868B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
US20060134012A1 (en) * 2002-12-16 2006-06-22 Symington John M Temporary pharmacologically-inactive dental coating for the in situ protection of dental therapeutic agents from saliva and abrasion from chewing
JP2006522790A (ja) * 2003-04-11 2006-10-05 ファイザー・インク エレトリプタンと重炭酸ナトリウムを含む医薬組み合わせ物
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
WO2005120456A2 (en) * 2004-06-09 2005-12-22 Pfizer Limited Formulation of eletriptan
WO2006013431A1 (en) * 2004-07-29 2006-02-09 Pfizer Limited Stable controlled-release pharmaceutical formulation of eletriptan
KR20070115918A (ko) * 2005-01-31 2007-12-06 교린 세이야꾸 가부시키 가이샤 멀티플 유닛형 경구 서방성 제제 및 그 제조방법
ES2434416T3 (es) 2005-08-10 2013-12-16 Add Advanced Drug Delivery Technologies, Ltd. Preparación oral con liberación controlada
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
EP2359830B1 (en) 2006-04-26 2012-09-19 Supernus Pharmaceuticals, Inc. Controlled released preparations of oxcarbazepine having sigmoidal release profile
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
US8137661B2 (en) 2007-07-25 2012-03-20 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of HCV infections using same
WO2011057676A1 (en) * 2009-11-16 2011-05-19 Evonik Röhm Gmbh A process for converting a solid (meth)acrylate copolymer into a dispersed form by means of a dispersing agent
FR3025425A1 (fr) * 2014-09-09 2016-03-11 Charleston Lab Inc Compositions pharmaceutiques
GB201716716D0 (en) * 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release

Also Published As

Publication number Publication date
NZ522976A (en) 2004-11-26
UY26861A1 (es) 2002-02-28
HUP0301453A2 (hu) 2003-08-28
CA2417887C (en) 2006-11-14
DE60114887D1 (de) 2005-12-15
TNSN01115A1 (fr) 2005-11-10
EP1365748B1 (en) 2005-11-09
EP1365748A2 (en) 2003-12-03
SK1082003A3 (en) 2004-09-08
DE60114887T2 (de) 2006-07-20
CN1630511A (zh) 2005-06-22
PA8523101A1 (es) 2002-08-26
NO20030498L (no) 2003-01-31
AR030099A1 (es) 2003-08-13
WO2002009675A1 (en) 2002-02-07
MXPA03000999A (es) 2003-06-09
AP2001002233A0 (en) 2001-09-30
JP2004505034A (ja) 2004-02-19
CZ2003241A3 (cs) 2004-02-18
ES2250429T3 (es) 2006-04-16
EE200300051A (et) 2004-10-15
EA200300110A1 (ru) 2003-06-26
CA2417887A1 (en) 2002-02-07
BR0112839A (pt) 2003-06-24
ZA200300868B (en) 2004-04-16
PE20020385A1 (es) 2002-05-11
IL153494A0 (en) 2003-07-06
WO2002009675A9 (en) 2003-07-10
PL359847A1 (en) 2004-09-06
NO20030498D0 (no) 2003-01-31
ATE308978T1 (de) 2005-11-15
US20020034545A1 (en) 2002-03-21
GT200100149A (es) 2002-06-25
BG107361A (bg) 2003-06-30
GB0018968D0 (en) 2000-09-20
SV2002000574A (es) 2002-12-02
MA26934A1 (fr) 2004-12-20
KR20030024820A (ko) 2003-03-26
OA12348A (en) 2004-03-19
ECSP034451A (es) 2003-03-10
HRP20030036A2 (en) 2003-04-30
IS6649A (is) 2002-12-05

Similar Documents

Publication Publication Date Title
JP2002532425A (ja) 新規な医薬製剤
CA2417887C (en) Particulate composition of eletriptan
JP2002523443A (ja) オメプラゾール製剤
JP2002531499A (ja) ゾルピデムまたはその塩からなる制御放出剤形
JP2001526213A (ja) 経口医薬パルス放出剤形
JPH11501948A (ja) プロトンポンプ阻害剤およびｎｓａｉｄからなる経口用医薬剤形
CA2130595A1 (en) Controlled release-initiation and controlled release-rate pharmaceutical composition
KR20100126465A (ko) 미코페놀레이트를 포함하는 변형 방출 제약 조성물 및 그것의 방법
KR20080007252A (ko) 양성 전립선 과다형성증용 치료 조합물
EP1781275B1 (en) Sustained release pharmaceutical composition of tolterodine
JP2003503340A (ja) 短時間型催眠薬またはその塩からなる二重持効性剤形
WO2006049564A1 (en) New modified release pellet formulations for proton pump inhibitors
EP1635795A1 (en) Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
JP2001517625A (ja) 活性成分放出制御薬物製剤
WO2004108117A2 (en) Extended release osmo-microsealed formulation comprising venlafaxine
CN101208078A (zh) 基于质子泵抑制剂的口服药剂
US6238703B1 (en) Controlled release oral dosage form of ketoprofen
WO2005053659A1 (en) An improved pharmaceutical formulation containing tamsulosin salt and a process for its preparation
WO2004024128A2 (en) Modified release ketoprofen dosage form
AU2003260620B2 (en) Microcapsules for the delayed, controlled release of perindopril
MXPA99002404A (en) Controlled release dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2. 2]oct-3-yl)acetonitrile monohydrochloride
MXPA00005895A (en) Oral pharmaceutical pulsed release dosage form

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application